September 11th 2025
Researchers will investigate a gene in the eye that is crucial for normal vision, but can cause retinal diseases when mutated that often lead to blindness.
Diagnosing CHRPE lesions can be a challenge for ODs
May 17th 2017A 26-year-old healthy ophthalmically asymptomatic female patient attended the University of Alabama School of Optometry clinic for a periodic ophthalmic evaluation. Her history was significant for myopic refractive correction, for which she wore soft contact lenses successfully.
The case of the blurred disc margins
March 13th 2017A 16-year-old female was scheduled for her periodic ophthalmic evaluation to update her spectacle lens prescription. At the visit, she reported a history of migraines, but the remainder of her personal and family medical history was non-contributory. She took no medications and had a history of low hyperopic refractive correction.
How a multi-component nutritional supplement benefits diabetic patients
May 9th 2016We all know the typical algorithm for our patients having diabetes: Maintain healthy blood sugar and pressure control, get annual dilated eye examinations, and receive laser or anti-VEGF therapy if and when they develop vision-threatening diabetic retinopathy (DR).
8 things you missed at ARVO and ACSRS 2016
May 9th 2016It’s been a busy week for ophthalmology research and news after both the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Seattle and the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in New Orleans.
Evaluating early-onset Stargardt disease
April 1st 2016A 33-year-old male attended to University of Alabama at Birmingham Eye Care complaining of blurry vision with either eye at both distance and near. He had a history of spectacle lens wear since childhood but also admitted to losing his glasses in most cases shortly after receiving them.
What’s new for diabetes management and prevention
January 6th 2016From new ways of predicting who will and won’t develop diabetes, to new diabetes meds, to new evidence regarding which anti-vascular endothelial growth factor (VEGF) might be better for your specific patient, the last year has given us better tools for helping our patients with diabetes.